AlphaMark Advisors LLC Sells 306 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

AlphaMark Advisors LLC cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.2% in the 3rd quarter, Holdings Channel reports. The firm owned 4,652 shares of the pharmaceutical company’s stock after selling 306 shares during the period. Vertex Pharmaceuticals accounts for about 0.7% of AlphaMark Advisors LLC’s holdings, making the stock its 25th largest position. AlphaMark Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,164,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Annapolis Financial Services LLC bought a new position in Vertex Pharmaceuticals in the first quarter valued at about $27,000. GHP Investment Advisors Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Stephens Consulting LLC bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Founders Capital Management increased its position in Vertex Pharmaceuticals by 50.0% during the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 25 shares in the last quarter. Finally, ZRC Wealth Management LLC bought a new position in Vertex Pharmaceuticals in the 1st quarter valued at approximately $39,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 2.4 %

VRTX opened at $498.73 on Friday. The company has a fifty day moving average price of $474.92 and a two-hundred day moving average price of $459.08. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64. The company has a market cap of $128.72 billion, a P/E ratio of -245.68 and a beta of 0.40. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The firm had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the firm earned $3.53 earnings per share. Analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In related news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total value of $1,086,990.00. Following the completion of the sale, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at approximately $11,088,728.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CMO Carmen Bozic sold 2,280 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total value of $1,086,990.00. Following the transaction, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at approximately $11,088,728.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Reshma Kewalramani sold 15,202 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total value of $7,555,394.00. Following the sale, the chief executive officer now directly owns 106,172 shares of the company’s stock, valued at $52,767,484. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,487 shares of company stock valued at $14,657,149 over the last ninety days. 0.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

VRTX has been the topic of a number of research reports. Barclays cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $472.00 to $509.00 in a research note on Monday, August 5th. Guggenheim upped their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $462.00 to $474.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 1st. HC Wainwright upped their price objective on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Finally, Oppenheimer lifted their target price on shares of Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $492.92.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.